title: Gamma-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers.
abstract: Blood products should be irradiated during allogeneic stem cell transplantation and before performing autologous stem cell harvest for prevention of acute transfusion-associated graft-versus-host disease (TA-GVHD). Usually, irradiation of all blood products is continued lifelong in the allogeneic setting. Up to now, no broadly accepted rules exist concerning autologous stem cell transplantation. We present here the results of an inquiry sent to 47 German transplantation centers regarding the transfusion policy following autologous stem cell transplantation. The results of 35 answering centers are included. Ten out of 35 centers offer irradiated blood products lifelong to their patients, mainly for the prevention of mistransfusion of non-irradiated blood components to allogeneic recipients. Twenty-two out of 35 centers administer irradiated blood products for a special time span after autologous stem cell transplantation. In most centers, this time span is from 3 to 6 months. Only few centers (4/35) expand this time span to 1-2 years after transplantation. A minority of centers (3/35) gave non-irradiated blood products to all of their patients or to patients not suffering from acute leukemia or after total body irradiation (TBI) containing preparative regimens. Most centers (19/35) deliver irradiated blood products irrespective of the conditioning regimen. Fifty-three percent of the centers decide to donate irradiated blood products not depending on immunological reconstitution. But in most centers some kind of hematological reconstitution is a major criterion for termination of irradiated blood products. Sixty-four percent of the centers made no difference in transfusion policy in regard to the underlying disease. No center experienced cases of proofed TA-GVHD. Guidelines should be worked out concerning transfusion policy after autologous stem cell transplantation.
authors.affiliation: Medizinische Klinik A, Klinikum Ludwigshafen GmbH, Bremserstrasse 79, 67063 Ludwigshafen/Rhein, Germany. weissb@klilu.de
authors.forename: B
authors.initials: B
authors.lastname: Weiss
authors.forename: M
authors.initials: M
authors.lastname: Hoffmann
authors.forename: C
authors.initials: C
authors.lastname: Anders
authors.forename: P
authors.initials: P
authors.lastname: Hellstern
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
authors.forename: M
authors.initials: M
authors.lastname: Uppenkamp
mesh_terms: D001769:Blood / Q000528:radiation effects*; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D005720:Gamma Rays; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D006291:Health Policy; D006801:Humans; D011159:Population Surveillance; D011182:Postoperative Care; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D014182:Transplantation, Autologous